Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.700
0.00 (0.00%)
At close: Mar 19, 2026, 4:00 PM EDT
1.620
-0.080 (-4.71%)
Pre-market: Mar 20, 2026, 9:13 AM EDT
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees decreased by 14 or -29.79% compared to the previous year.
Employees
33
Change (1Y)
-14
Growth (1Y)
-29.79%
Revenue / Employee
$46,848
Profits / Employee
-$1,910,848
Market Cap
172.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 33 | -14 | -29.79% |
| Dec 31, 2023 | 47 | 8 | 20.51% |
| Dec 31, 2022 | 39 | 10 | 34.48% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | 28 | -2 | -6.67% |
| Sep 30, 2020 | 28 | -2 | -6.67% |
| Jun 30, 2020 | 28 | 5 | 21.74% |
| Mar 31, 2020 | 30 | 10 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ProQR Therapeutics | 166 |
| Molecular Partners AG | 153 |
| Adagene | 138 |
| Cartesian Therapeutics | 75 |
| Tenaya Therapeutics | 70 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
MIST News
- 2 hours ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - GlobeNewsWire
- 6 hours ago - Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 4 days ago - Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - GlobeNewsWire
- 8 days ago - Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - GlobeNewsWire
- 22 days ago - Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - GlobeNewsWire
- 6 weeks ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire